Advisory Alpha LLC Makes New Investment in DexCom, Inc. $DXCM

Advisory Alpha LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,704 shares of the medical device company’s stock, valued at approximately $236,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in DexCom by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after buying an additional 925,882 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after purchasing an additional 2,879,489 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of DexCom by 22.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares in the last quarter. Nuveen LLC acquired a new stake in shares of DexCom in the 1st quarter valued at $554,893,000. Finally, Raymond James Financial Inc. raised its holdings in shares of DexCom by 21.8% in the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock valued at $229,117,000 after purchasing an additional 601,088 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director directly owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. This trade represents a 5.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares of the company’s stock, valued at $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 5,383 shares of company stock valued at $434,274. Company insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Oppenheimer lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Piper Sandler set a $100.00 price objective on shares of DexCom and gave the company an “overweight” rating in a report on Tuesday, October 21st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Thursday, July 31st. The Goldman Sachs Group reduced their price objective on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Finally, Citigroup reduced their price objective on shares of DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $97.19.

DexCom Trading Up 0.0%

NASDAQ DXCM opened at $68.20 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The firm’s fifty day moving average price is $71.42 and its 200 day moving average price is $77.96. The company has a market capitalization of $26.74 billion, a price-to-earnings ratio of 47.36, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company’s revenue was up 21.6% on a year-over-year basis. During the same period last year, the firm posted $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.